Cell therapy data shows ability to reset the immune system in severe immunological diseases, potentially delivering dramatic responses that reverse disease progression by decades.

Radioligand therapy links radioactive particles to drugs that micro-target tumors, opening a whole new area of medicine where Novartis is a pioneer.

European governments commoditize innovation through budget constraints and artificial generic pricing, causing market size to halve versus US, $250B in manufacturing announcements moving to…

China modernized regulation, created national reimbursement and value-based pricing, achieving fastest clinical trial startup/recruitment globally, regulator speed matching US, and novel dr…

Balkanizing clinical trial data acceptance between US and China would significantly set back drug timelines because global recruitment relies on Asia for pace, and dual approvals maximize r…